论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
特发性肺纤维化(IPF)治疗中 LPA-LPAR1 和 VEGF-VEGFR2 信号传导的抑制
Authors Luo YL, Li Y, Zhou W, Wang SY, Liu YQ
Received 2 April 2023
Accepted for publication 25 July 2023
Published 2 September 2023 Volume 2023:17 Pages 2679—2690
DOI https://doi.org/10.2147/DDDT.S415453
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tuo Deng
Abstract: Due to the complex mechanism and limited treatments available for pulmonary fibrosis, the development of targeted drugs or inhibitors based on their molecular mechanisms remains an important strategy for prevention and treatment. In this paper, the downstream signaling pathways mediated by VEGFR and LPAR1 in pulmonary cells and the role of these pathways in pulmonary fibrosis, as well as the current status of drug research on the targets of LPAR1 and VEGFR2, are described. The mechanism by which these two pathways regulate vascular leakage and collagen deposition leading to the development of pulmonary fibrosis are analyzed, and the mutual promotion of the two pathways is discussed. Here we propose the development of drugs that simultaneously target LPAR1 and VEGFR2, and discuss the important considerations in targeting and safety.
Keywords: idiopathic pulmonary fibrosis, VEGFR2, LPAR1